SAN DIEGO, November 22, 2021 – Locanabio, Inc., a genetic medicines company developing therapeutics for patients with severe neuromuscular, neurodegenerative and retinal diseases, today announced that its leadership team will participate in the following upcoming investor conferences:
Locanabio is a leader in developing a new class of genetic medicines that has the potential to significantly improve the lives of patients with devastating genetic diseases by correcting the message of disease-causing RNA. Our proprietary platform, CORRECTx™, uses gene therapy to deliver RNA-binding protein systems that can be engineered to selectively manipulate disease-causing RNA by multiple mechanisms. Our systems are designed to provide a durable therapy with a single administration without altering a cell’s DNA. Locanabio’s CORRECTx platform has applications across a range of tissues and diseases and we are currently advancing programs in neurodegenerative, neuromuscular and retinal diseases. For more information, visit www.locanabio.com.
Jenna Urban
Berry & Company
jurban@berrypr.com
+1-212-253-8881